Cost Effectiveness

A cost-effectiveness analysis was conducted as part of the Pathways to Completion Study. In the LTBI component, the peer-monitored group was found to have similar costs to the current clinical practice group. The peer program was calculated to cost only $50 to achieve an additional completion of LTBI treatment and $686 to avoid a case of TB. Given the potential complications of untreated LTBI, this is a highly cost-effective approach. In the TB component, significant differences between the two DOT models were not found for costs or completion. This suggests that the clinic-based surrogate family model DOT can achieve TB treatment completion rates comparable to community-based DOT in a highly cost-effective manner.